ANGPTL4 and Caveolin-1 as potential novel biomarkers for metabolic syndrome in Iraqi adults over 50

Haitham Ibrahim Azrak; Entedhar Rifaat Sarhat

doi:10.62838/amsm-2026-0007

.blurhash-client-img { display: none !important; }

ANGPTL4 and Caveolin-1 as potential novel biomarkers for metabolic syndrome in Iraqi adults over 50

Acta Marisiensis - Seria Medica

Volume 72 (2026): Issue 2 (June 2026)

By: Haitham Ibrahim Azrak and Entedhar Rifaat Sarhat

Open Access

|Jul 2026

Abstract

Background: Background: Metabolic syndrome (MetS) is a cluster of risk factors, including abdominal obesity, dyslipidemia, hyperglycemia and hypertension that markedly elevate the incidence of cardiovascular diseases and type 2 diabetes.

Objective: This study aimed to evaluate the diagnostic value of serum angiopoietin-like protein 4 (ANGPTL4) and Caveolin-1 (Cav-1), as novel agents in diagnosing MetS in patients older than 50 years.

Methods: A case-control study (January–April 2025) included 60 cases with MetS and 30 matched-healthy participants of the same gender and age (>50 years) from hospitals in Diyala Governorate, Iraq. MetS was diagnosed by harmonized definition (≥3 features: elevated waist diameter, triglyceride ≥150 mg/dL, low HDL-C, BP ≥130/85 mmHg and fasting glucose ≥100 mg/dL).

Results: Serum ANGPTL4 (142.78 ± 22.53 vs. 69.29 ± 30.80 ng/mL, p-value <0.001) and Cav-1 (16.12 ± 2.87 vs. 8.51 ± 1.59 ng/mL, p-value <0.001) were significantly elevated in the MetS group. Receiver Operating Characteristic (ROC) analysis demonstrated exceptional diagnostic performance, with an Area Under the Curve (AUC) of 0.97 for ANGPTL4 and 0.99 for Cav-1. Binary logistic regression analysis identified both biomarkers as significant independent predictors of MetS.

Conclusion: Serum ANGPTL4 and Caveolin-1 levels exhibited outstanding diagnostic performance for MetS in Iraqi adults aged >50 years, reflecting underlying lipid dysregulation and endothelial dysfunction. These biomarkers showed significant potential for enhancing early detection and clinical management, warranting validation in a broader population.

References

Chew NWS, Ng CH, Tan DJH, Kong G, Lin C, Chin YH, et al. The global burden of metabolic disease: Data from 2000 to 2019. Cell Metab 2023;35:414-428.e3. https://doi.org/10.1016/j.cmet.2023.02.003.
Search in Google Scholar Back to article
Neeland IJ, Lim S, Tchernof A, Gastaldelli A, Rangaswami J, Ndumele CE, et al. Metabolic syndrome. Nat Rev Dis Prim 2024;10:60–77. https://doi.org/10.1038/s41572-024-00563-5.
Search in Google Scholar Back to article
Nwankwo M, Okamkpa CJ, Danborno B. Comparison of diagnostic criteria and prevalence of metabolic syndrome using WHO, NCEP-ATP III, IDF and harmonized criteria: A case study from urban southeast Nigeria. Diabetes Metab Syndr Clin Res Rev 2022;16:1–34.
Search in Google Scholar Back to article
Fahed G, Aoun L, Bou Zerdan M, Allam S, Bou Zerdan M, Bouferraa Y, et al. Metabolic syndrome: updates on pathophysiology and management in 2021. Int J Mol Sci 2022;23:786.
Search in Google Scholar Back to article
Liu L, Cai X-C, Sun X-Y, Zhou Y-Q, Jin M-Z, Wang J, et al. Global prevalence of metabolic syndrome in patients with psoriasis in the past two decades: current evidence. J Eur Acad Dermatol Venereol 2022;36:1969–79. https://doi.org/10.1111/jdv.18296.
Search in Google Scholar Back to article
Liang X, Or B, Tsoi MF, Cheung CL, Cheung BMY. Prevalence of metabolic syndrome in the United States National Health and Nutrition Examination Survey 2011–18. Postgrad Med J 2023;99:985–92. https://doi.org/10.1093/postmj/qgad008.
Search in Google Scholar Back to article
Jamali Z, Ayoobi F, Jalali Z, Bidaki R, Lotfi MA, Esmaeili-Nadimi A, et al. Metabolic syndrome: a population-based study of prevalence and risk factors. Sci Rep 2024;14:3987. https://doi.org/10.1038/s41598-024-54367-4.
Search in Google Scholar Back to article
Hung C-C, Zhen Y-Y, Niu S-W, Lin K-D, Lin HY-H, Lee J-J, et al. Predictive Value of HbA1c and Metabolic Syndrome for Renal Outcome in Non-Diabetic CKD Stage 1-4 Patients. Biomedicines 2022;10:1–10. https://doi.org/10.3390/biomedicines10081858.
Search in Google Scholar Back to article
Kharazmi-Khorassani S, Kharazmi-Khorassani J, Rastegar-Moghadam A, Samadi S, Ghazizadeh H, Tayefi M, et al. Association of a genetic variant in the angiopoietin-like protein 4 gene with metabolic syndrome. BMC Med Genet 2019;20:1–6. https://doi.org/10.1186/s12881-019-0825-8.
Search in Google Scholar Back to article
Aryal B, Price NL, Suarez Y, Fernández-Hernando C. ANGPTL4 in Metabolic and Cardiovascular Disease. Trends Mol Med 2019;25:723–34. https://doi.org/10.1016/j.molmed.2019.05.010.
Search in Google Scholar Back to article
Chen J, Luo Q, Yi Y, Wang J, Chen P, Luo F, et al. ANGPTL3 as a target for treating lipid disorders in type 2 diabetes patients. Lipids Health Dis 2024;23:1–9.
Search in Google Scholar Back to article
Zuo Y, He Z, Chen Y, Dai L. Dual role of ANGPTL4 in inflammation. Inflamm Res Off J Eur Histamine Res Soc . [et Al] 2023;72:1303–13. https://doi.org/10.1007/s00011-023-01753-9.
Search in Google Scholar Back to article
Abaj F, Saeedy SAG, Mirzaei K. Are caveolin-1 minor alleles more likely to be risk alleles in insulin resistance mechanisms in metabolic diseases? BMC Res Notes 2021;14:1–8.
Search in Google Scholar Back to article
Peng H, Mu P, Li H, Lin S, Lin C, Lin K, et al. Caveolin-1 Is Essential for the Improvement of Insulin Sensitivity through AKT Activation during Glargine Treatment on Diabetic Mice. J Diabetes Res 2021;2021:1–9. https://doi.org/10.1155/2021/9943344.
Search in Google Scholar Back to article
Mysling S, Kristensen KK, Larsson M, Kovrov O, Bensadouen A, Jørgensen TJD, et al. The angiopoietin-like protein ANGPTL4 catalyzes unfolding of the hydrolase domain in lipoprotein lipase and the endothelial membrane protein GPIHBP1 counteracts this unfolding. Elife 2016;5:1–9. https://doi.org/10.7554/eLife.20958.
Search in Google Scholar Back to article
Estefes-Duarte JA, Espinosa-Sánchez A, Pérez-Hernández N, Ortiz MI, Fernández-Martínez E. Mechanisms of Bioactive Lipids to Modulate Master Regulators of Lipid Homeostasis and Inflammation in Metabolic Syndrome. Curr Pharm Biotechnol 2024;26:1755–76.
Search in Google Scholar Back to article
Sylvers-Davie KL, Davies BSJ. Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8. Am J Physiol Endocrinol Metab 2021;321:E493–508. https://doi.org/10.1152/ajpendo.00195.2021.
Search in Google Scholar Back to article
Arefian M, Mazaheri-Tehrani S, Yazdi M, Kelishadi R. Caveolin Gene, a Possible Risk Factor for Metabolic Syndrome in Humans: A Systematic Review and Meta-Analysis. Int J Prev Med 2025;16:1–8.
Search in Google Scholar Back to article
Boscher C, Nabi IR. Caveolin-1: role in cell signaling. Adv Exp Med Biol 2012;729:29–50. https://doi.org/10.1007/978-1-4614-1222-9_3.
Search in Google Scholar Back to article
Simón L, Campos A, Leyton L, Quest AFG. Caveolin-1 function at the plasma membrane and in intracellular compartments in cancer. Cancer Metastasis Rev 2020;39:435–53. https://doi.org/10.1007/s10555-020-09890-x.
Search in Google Scholar Back to article
Yaikwawong M, Ek-eudomsuk P, Sittithumcharee G, Anupunpisit V, Peerapatdit T, Deerochanawong C, et al. A prevalent caveolin-1 gene rs926198 variant is associated with type 2 diabetes mellitus in the Thai population. Sci Rep 2024;14:1–9. https://doi.org/10.1038/s41598-024-78534-9.
Search in Google Scholar Back to article
Baudrand R, Goodarzi MO, Vaidya A, Underwood PC, Williams JS, Jeunemaitre X, et al. A prevalent caveolin-1 gene variant is associated with the metabolic syndrome in Caucasians and Hispanics. Metabolism 2015;64:1674–81. https://doi.org/10.1016/j.metabol.2015.09.005.
Search in Google Scholar Back to article
Fan K-C, Chen S-C, Yen I-W, Lin C-H, Kuo C-H, Lyu Y-P, et al. Plasma angiopoietin-like protein 4 as a novel biomarker predicting 10-year mortality in a community-based population: a longitudinal cohort study. Arch Med Sci 2025;21:51–9. https://doi.org/10.5114/aoms/189504.
Search in Google Scholar Back to article
Gharipour M, Nezafati P, Sadeghian L, Eftekhari A, Rothenberg I, Jahanfar S. Precision medicine and metabolic syndrome. ARYA Atheroscler 2022;18:1–10. https://doi.org/10.22122/arya.2022.26215.
Search in Google Scholar Back to article
Gesteiro E, Megía A, Guadalupe-Grau A, Fernandez-Veledo S, Vendrell J, González-Gross M. Early identification of metabolic syndrome risk: A review of reviews and proposal for defining pre-metabolic syndrome status. Nutr Metab Cardiovasc Dis 2021;31:2557–74. https://doi.org/ https://doi.org/10.1016/j.numecd.2021.05.022.
Search in Google Scholar Back to article
Cho Y, Lee SY. Useful Biomarkers of Metabolic Syndrome. Int J Environ Res Public Health 2022;19. https://doi.org/10.3390/ijerph192215003.
Search in Google Scholar Back to article
Srikanthan K, Feyh A, Visweshwar H, Shapiro JI, Sodhi K. Systematic Review of Metabolic Syndrome Biomarkers: A Panel for Early Detection, Management, and Risk Stratification in the West Virginian Population. Int J Med Sci 2016;13:25–38. https://doi.org/10.7150/ijms.13800.
Search in Google Scholar Back to article
Pearson ER. Personalized medicine in diabetes: the role of ‘omics’ and biomarkers. Diabet Med 2016;33:712–7. https://doi.org/https://doi.org/10.1111/dme.13075.
Search in Google Scholar Back to article
Islam MS, Wei P, Suzauddula M, Nime I, Feroz F, Acharjee M, et al. The interplay of factors in metabolic syndrome: understanding its roots and complexity. Mol Med 2024;30:1–21. https://doi.org/10.1186/s10020-024-01019-y.
Search in Google Scholar Back to article
Bovolini A, Garcia J, Andrade MA, Duarte JA. Metabolic Syndrome Pathophysiology and Predisposing Factors. Int J Sports Med 2021;42:199–214. https://doi.org/10.1055/a-1263-0898.
Search in Google Scholar Back to article
de Souza GM, de Albuquerque Borborema ME, de Lucena TMC, da Silva Santos AF, de Lima BR, de Oliveira DC, et al. Caveolin-1 (CAV-1) up regulation in metabolic syndrome: all roads leading to the same end. Mol Biol Rep 2020;47:9245–50. https://doi.org/10.1007/s11033-020-05945-y.
Search in Google Scholar Back to article
Rafaqat S, Sharif S, Majeed M, Naz S, Manzoor F, Rafaqat S. Biomarkers of Metabolic Syndrome: Role in Pathogenesis and Pathophysiology Of Atrial Fibrillation. J Atr Fibrillation 2021;14:1–9. https://doi.org/10.4022/jafib.20200495.
Search in Google Scholar Back to article
Ilow R, Regulska-Ilow B, Różańska D, Kowalisko A, Biernat J. Prevalence of metabolic syndrome among 40- and 50-year-old inhabitants of Wroclaw, Poland. Ann Agric Environ Med 2012;19:551–6.
Search in Google Scholar Back to article
Holmannova D, Borsky P, Andrys C, Kremlacek J, Fiala Z, Parova H, et al. The Influence of Metabolic Syndrome on Potential Aging Biomarkers in Participants with Metabolic Syndrome Compared to Healthy Controls. Biomedicines 2024;12:1–15. https://doi.org/10.3390/biomedicines12010242.
Search in Google Scholar Back to article
Hooshmand E, Akbarzade I, Delbari D, Niroomand M, Ghavidel F, Saatchi M. Prevalence of Metabolic Syndrome Among Adults Aged 50 and Above and Associated Factors: A Cross-Sectional Study From Ardakan Cohort Study on Aging (ACSA). Heal Sci Reports 2025;8:1–7. https://doi.org/https://doi.org/10.1002/hsr2.70508.
Search in Google Scholar Back to article

Articles in this issue

DOI: https://doi.org/10.62838/amsm-2026-0007 | Journal eISSN: 2668-7763 | Journal ISSN: 2668-7755

Journal RSS Feed

Language: English

Page range: 98 - 104

Submitted on: Dec 18, 2025

Accepted on: Apr 6, 2026

Published on: Jul 3, 2026

Published by: University of Medicine, Pharmacy, Science and Technology of Targu Mures

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

ANGPTL4,

Related subjects:

Clinical medicine, other

© 2026 Haitham Ibrahim Azrak, Entedhar Rifaat Sarhat, published by University of Medicine, Pharmacy, Science and Technology of Targu Mures
This work is licensed under the Creative Commons Attribution 4.0 License.

Volume 72 (2026): Issue 2 (June 2026)